GLI1 and breast cancer: One potential source of such biomarkers and therapeutical targets is the HH-GLI pathway, a developmental signaling pathway whose role in BC etiopathology and significant overexpression of pathway’s members in BC tissues compared to healthy controls have been confirmed in a multitude of studies (reviewed in [13]).